Diasome Announces Positive Results for HDV Insulin Additive to Manage Blood Sugar
Diasome Pharmaceuticals announced positive results this week from a Phase 2 study of its injectable hepatocyte directed vesicle (HDV) additive for insulin in patients with type 1 diabetes. The news could prove a major step forward for therapies that aim to improve and optimize the way insulin is used and metabolized by the body. In …
2020 Data: Current Insights from the T1D Exchange Registry
The T1D Exchange Registry launched last year, and it’s begun to provide a fascinating and vital look into some of the more detailed aspects of life with type 1 diabetes. From your age of diagnosis to frequency of testing, we’ve learned more about how you’re living, working, and caring for diabetes across the country.
Securing Patient Data: T1D Exchange and National Data Privacy Day
Today, January 28th, has been designated by the Council of Europe as Data Privacy and Protection Day since 2007, and recognized two years later by the U.S. Congress in 2009.
Pharma and Medtech CEOs at JPMorgan 2020 Weigh in on Insulin Pricing, Supply Issues, and Innovation
Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.
T1D Exchange Registry – Our User-Friendly Way to Participate in Type 1 Diabetes Research
The T1D Exchange Registry is a collection of individuals with type 1 diabetes and their supporters who participate in research. Adults with type 1 diabetes or parents of children with type 1 diabetes can join by registering online, providing consent, and completing a short 28-question survey. Participants will then be asked to complete a similar questionnaire once a year. Once registered, participants will also have the ability to take part in more research opportunities in the future.
Tandem CCO Brian Hansen Discusses FDA Approval for Control IQ Algorithm with t:slim X2
Last month, the FDA approved the Tandem Diabetes Care update to its t:slim X2 insulin pump Control-IQ technology, clearing the way for the first automated and interoperable insulin dosing system on the U.S. market.
FDA Approves Fiasp Ultra-Fast Acting Insulin for Children with Type 1 Diabetes
The U.S. Food and Drug Administration has approved Novo Nordisk’s fast-acting Fiasp insulin for use in children as well as adults, the pharmaceutical firm announced Monday.